Core Viewpoint - The company is advancing its clinical research with a focus on innovative therapies for bladder cancer and EBV-related malignancies [2] Group 1: Product Development - The company is in Phase III clinical trials for a therapeutic Bacillus Calmette-Guérin (BCG) vaccine aimed at treating non-muscle invasive bladder cancer and preventing recurrence after transurethral resection of Ta or T1 stage bladder papilloma [2] - The company is also conducting preclinical research on an EBV vaccine intended to prevent malignancies associated with Epstein-Barr virus [2] - Ongoing product development updates will be disclosed through the company's information channels [2]